
ASRT
Assertio Holdings Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.685899
Open
0.670
VWAP
0.67
Vol
196.37K
Mkt Cap
64.46M
Low
0.660
Amount
132.37K
EV/EBITDA(TTM)
10.46
Total Shares
95.12M
EV
16.06M
EV/OCF(TTM)
2.53
P/S(TTM)
0.54
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
30.22M
-6.11%
--
--
29.30M
+0.34%
--
--
27.97M
-10.15%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Assertio Holdings, Inc. (ASRT) for FY2025, with the revenue forecasts being adjusted by -1.33% over the past three months. During the same period, the stock price has changed by 13.20%.
Revenue Estimates for FY2025
Revise Downward

-1.33%
In Past 3 Month
Stock Price
Go Up

+13.20%
In Past 3 Month
5 Analyst Rating

316.05% Upside
Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is 2.80 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy

316.05% Upside
Current: 0.673

Low
1.50
Averages
2.80
High
3.50

316.05% Upside
Current: 0.673

Low
1.50
Averages
2.80
High
3.50
Alliance Global Partners
Buy
maintain
2025-05-13
Reason
Alliance Global Partners
Price Target
2025-05-13
maintain
Buy
Reason
Alliance Global Partners lowered the firm's price target on Assertio to $1.50 from $1.75 and keeps a Buy rating on the shares following the Q1 report. The company's Q1 revenue was below forecast driven largely by Rolvedon, the analyst tells investors in a research note. Now that Assertio appears to have cleaned up the opioid overhang litigation, the share price should start tracking Rolvedon, for better or worse, contends Alliance Global .
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$4 → $3.5
2025-03-19
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$4 → $3.5
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$4
2024-12-16
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$4
2024-12-16
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$4
2024-11-25
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$4
2024-11-25
Reiterates
Strong Buy
Reason
Maxim Group
Naz Rahman
Strong Buy
Initiates
$3
2024-07-26
Reason
Maxim Group
Naz Rahman
Price Target
$3
2024-07-26
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Assertio Holdings Inc (ASRT.O) is -2.79, compared to its 5-year average forward P/E of 6.99. For a more detailed relative valuation and DCF analysis to assess Assertio Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
6.99
Current PE
-2.79
Overvalued PE
91.95
Undervalued PE
-77.98
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
2.73
Current EV/EBITDA
1.48
Overvalued EV/EBITDA
4.19
Undervalued EV/EBITDA
1.27
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
0.93
Current PS
0.54
Overvalued PS
1.37
Undervalued PS
0.50
Financials
Annual
Quarterly
FY2025Q1
YoY :
-18.37%
26.49M
Total Revenue
FY2025Q1
YoY :
+257.87%
-12.94M
Operating Profit
FY2025Q1
YoY :
+200.24%
-13.54M
Net Income after Tax
FY2025Q1
YoY :
+180.00%
-0.14
EPS - Diluted
FY2025Q1
YoY :
-267.00%
-12.54M
Free Cash Flow
FY2025Q1
YoY :
-25.83%
35.75
Gross Profit Margin - %
FY2025Q1
YoY :
-77.28%
5.35
FCF Margin - %
FY2025Q1
YoY :
+267.77%
-51.12
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
70.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
70.0K
USD
Months
0-12
0
0.0
USD
Months
ASRT News & Events
Events Timeline
2024-12-17 (ET)
2024-12-17
07:34:13
Assertio Holdings appoints Mark Reisenauer to board of directors

2024-12-13 (ET)
2024-12-13
07:03:44
Assertio Holdings announces results of Rolvedon injection study

2024-12-12 (ET)
2024-12-12
07:05:59
Assertio Holdings appoints Schwichtenberg as CTO, Pietrya as CCO

Sign Up For More Events
Sign Up For More Events
News
4.0
06-18NASDAQ.COMNew Strong Sell Stocks for June 18th
4.0
05-19BenzingaHC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $3.5 Price Target
9.5
05-12SeekingAlphaAssertio Holdings GAAP EPS of -$0.14 misses by $0.08, revenue of $26.49M misses by $1.03M
Sign Up For More News
People Also Watch

AUBN
Auburn National Bancorporation Inc
28.470
USD
+2.78%

ATMC
Alphatime Acquisition Corp
12.000
USD
0.00%

VIGL
Vigil Neuroscience Inc
8.070
USD
-0.12%

PBHC
Pathfinder Bancorp Inc (MARYLAND)
15.250
USD
+0.07%

CTM
Castellum Inc
1.490
USD
+6.43%

CAPN
Cayson Acquisition Corp
10.370
USD
+0.39%

EPIX
ESSA Pharma Inc
1.880
USD
+0.53%

INCR
InterCure Ltd
1.520
USD
+1.33%

XCH
XCHG Ltd
1.300
USD
-0.76%

CATO
Cato Corp
2.820
USD
+0.36%
FAQ

What is Assertio Holdings Inc (ASRT) stock price today?
The current price of ASRT is 0.673 USD — it has increased 0.45 % in the last trading day.

What is Assertio Holdings Inc (ASRT)'s business?

What is the price predicton of ASRT Stock?

What is Assertio Holdings Inc (ASRT)'s revenue for the last quarter?

What is Assertio Holdings Inc (ASRT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Assertio Holdings Inc (ASRT)'s fundamentals?

How many employees does Assertio Holdings Inc (ASRT). have?
